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Background:	Both	one‐stage	(OSA)	and	chromogenic	substrate	assays	(CSA)	are	used	
to	measure	factor	VIII	(FVIII)	activity.	Factors	explaining	analytical	variation	in	FVIII	
activity	levels	are	still	to	be	completely	elucidated.
Aim:	The	aim	of	this	study	was	to	investigate	and	quantify	the	analytical	variation	in	
OSA	and	CSA.
Methods:	Factors	determining	analytical	variation	were	studied	in	sixteen	lyophilized	
plasma	samples	 (FVIII	activity	<0.01‐1.94	IU/mL)	and	distributed	by	 the	ECAT	sur‐
veys.	To	elucidate	the	causes	of	OSA	variation,	we	exchanged	deficient	plasma	be‐
tween	three	company	set‐ups.
Results:	On	 average,	 206	 (range	 164‐230)	 laboratories	 used	 the	OSA	 to	measure	
FVIII	activity	and	30	(range	12‐51)	used	CSA.	The	coefficient	of	variation	of	OSA	and	
CSA	increased	with	lower	FVIII	levels	(FVIII	<0.05	IU/mL).	This	resulted	in	misclassi‐
fication	of	 a	 severe	haemophilia	A	 sample	 into	 a	moderate	or	mild	haemophilia	A	
sample	 in	 4/30	 (13.3%)	 of	CSA	measurements,	while	 this	was	37/139	 (26.6%)	 for	
OSA.	 OSA	measurements	 performed	with	 reagents	 and	 equipment	 from	Werfen	
showed	slightly	lower	FVIII	activity	(0.93,	IQR	0.88‐0.98	IU/mL)	compared	to	meas‐
urements	with	Stago	(1.07,	IQR	1.02‐1.14	IU/mL)	and	Siemens	(1.03,	IQR	0.97‐1.07	IU/
mL).	Part	of	this	difference	is	explained	by	the	value	of	the	calibrator.	For	CSA,	the	
measured	FVIII	levels	were	similar	using	the	different	kits.
Conclusions:	In	the	lower	range	(<0.05	IU/mL),	analytical	variation	of	FVIII	measure‐
ments	 is	high	 in	both	OSA	and	CSA	measurements.	The	variation	 in	FVIII	 activity	
levels	 was	 partly	 explained	 by	 specific	manufacturers.	 Further	 standardization	 of	
FVIII	measurements	and	understanding	of	analytical	variation	is	required.
K E Y W O R D S
factor	VIII,	FVIII	measurements,	haemophilia	A
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution‐NonCommercial‐NoDerivs	License,	which	permits	use	and	distribution	in	
any	medium,	provided	the	original	work	is	properly	cited,	the	use	is	non‐commercial	and	no	modifications	or	adaptations	are	made.
©	2018	The	Authors.	Haemophilia	Published	by	John	Wiley	&	Sons	Ltd
2  |     van MOORT eT al.
1  | INTRODUC TION
Correct	classification	of	haemophilia	A	severity	is	important	as	treat‐
ment	intensity	is	based	on	categorization.1	Severe	(factor	VIII	[FVIII]	
activity	levels	<0.01	IU/mL)	and	some	moderate	(FVIII	activity	levels	
0.01‐0.05	IU/mL)	haemophilia	patients	receive	prophylactic	replace‐
ment	therapy	to	prevent	spontaneous	bleeding	in	joints	and	muscles	
while	mild	haemophilia	A	patients	(FVIII	activity	levels	0.05‐0.40	IU/
mL)	receive	desmopressin	or	replacement	therapy	only	 in	cases	of	
trauma	and/or	surgery.1,2	Measuring	FVIII	activity	levels	accurately	
and	reproducibly	in	different	laboratories	is	therefore	essential.	We	
recently	showed	that	despite	excellent	performance	in	the	ECAT	ex‐
ternal	quality	assessment	programme,	between‐laboratory	variation	
may	result	in	different	FVIII	levels,	and	consequently,	in	misclassifi‐
cation	of	haemophilia	severity.4	Limited	between‐laboratory	varia‐
tion	in	FVIII	activity	levels	is	also	of	importance	for	the	monitoring	
of	treatment	in	patients	with	haemophilia	A,	as	specific	target	FVIII	
activity	 levels	 should	 be	maintained	 around	 surgery	 and	 bleeding	
episodes.1,2,5
Two	assays	are	widely	used	to	measure	FVIII	activity:	the	one‐
stage	assay	(OSA)	and	the	two‐stage	chromogenic	substrate	assay	
(CSA).	Most	 laboratories	use	 the	OSA,	which	 is	based	on	 the	ac‐
tivated	 partial	 thromboplastin	 time	 (APTT),	 using	 the	 time	 until	
clot	formation	as	its	endpoint.6	In	the	CSA,	the	coagulation	system	
is	 triggered	resulting	 in	 the	generation	of	 factor	Xa	 (FXa).7	 In	 the	
second	step	of	this	test,	FXa	hydrolyses	a	chromogenic	substrate	
causing	a	colour	change,	which	reflects	the	amount	of	FVIII	activity	
left	 in	 the	 patient	 sample.	 The	 endpoint	 in	 the	CSA	 differs	 from	
that	 in	OSA,	 as	 the	CSA	measures	extinction	 at	 a	plateau	phase.	
Discrepancies	 in	 FVIII	 activity	 levels	 have	 been	 extensively	 re‐
ported	between	 these	 two	assays,	depending	on	 the	mutation	 in	
F8	gene.8,9
Nowadays,	 reagents	 and	 equipment	 to	 perform	 FVIII	 activity	
measurements	are	widely	available.	The	use	of	varying	products	may	
partially	 explain	 the	 between‐laboratory	 variation	 in	 FVIII	 results.	
However,	 it	 is	still	unclear	what	the	precise	 impact	 is	of	varying	 in	
reagents	and	equipment	on	the	variability	of	FVIII	activity	measure‐
ments.11,12	A	possible	explanation	may	be	that	particular	companies	
provide	the	majority	of	products	applied	for	the	haemostatic	testing	
which	is	standard	in	haemophilia.	Most	reports	focus	on	the	specific	
reagents	of	one	company,12,15,16	rather	than	analysing	a	test	system	
from	one	company	which	consists	of	calibrator,	activator,	deficient	
plasma	and	equipment.	As	this	is	often	the	case	in	real	life	situations,	
causal	factors	leading	to	the	variation	in	FVIII	activity	levels	should	
be	investigated	more	extensively.
To	improve	quality	of	measurements	in	haemostasis	laborato‐
ries,	laboratories	follow	international	guidelines	and	participate	in	
external	quality	control	surveys.	The	data	from	the	ECAT	external	
quality	 assessments	 indeed	 show	 that	 laboratories	 use	 all	 com‐
ponents	 for	 the	FVIII	 assays	 from	one	 company	 in	 a	majority	of	
cases.	Therefore,	ECAT	data	are	highly	suitable	to	investigate	the	
influence	of	company	set‐ups	on	FVIII	activity	level	variation.	The	
aim	of	 this	 study	 is	 to	 investigate	and	quantify	variation	 in	FVIII	
activity	when	testing	by	OSA	and	CSA	in	surveys	conducted	by	the	
ECAT	foundation.	 In	addition,	we	studied	effects	of	replacement	
of	selected	reagents	in	the	OSA	with	those	from	another	company	
on	FVIII	results.
2  | MATERIAL AND METHODS
2.1 | Quantifying variation in FVIII activity 
measurements
More	than	200	laboratories	working	in	the	field	of	haemostasis	
and	thrombosis	participate	in	the	ECAT	external	quality	assess‐
ment	programme	for	FVIII.	Four	times	per	year,	two	lyophilized	
plasma	samples	are	distributed.	To	quantify	the	variation	in	FVIII	
activity	 measurements,	 we	 selected	 sixteen	 samples	 (a)	 with	
FVIII	 activity	 levels	 between	<0.01	 and	 1.94	IU/mL	 (consensus	
values),	 (b)	 measured	 by	more	 than	 10	 laboratories	 by	OSA	 or	
CSA	 and	 (c)	 measured	 between	 2010	 and	 2016.	 As	 expected,	
we	 found	 that	 most	 laboratories	 use	 the	 calibrator,	 activator,	
deficient	plasma	and	equipment	from	one	company	in	the	OSA.	
Therefore,	 three	 groups	 were	 created	 from	 the	 three	 largest	
companies	to	compare	the	CVs	in	the	OSA:	(a)	Siemens,	(b)	Stago	
and	(c)	Werfen.
To	 investigate	 the	 impact	 of	 variation	 on	 hypothetical	 haemo‐
philia	 severity	diagnoses	which	 are	 solely	based	on	 laboratory	 re‐
sults,	FVIII	activity	levels	were	subsequently	classified	according	to	
severity	type	as	stated	by	the	World	Federation	of	Haemophilia.1
2.2 | Impact of test system on FVIII activity levels 
in the OSA
From	the	ECAT	external	quality	assessment	programme,	four	plasma	
samples	were	chosen	with	different	FVIII	activity	levels	to	investigate	
the	influence	of	the	test	system	on	the	FVIII	activity	levels.	To	cover	
the	range	of	FVIII	activity	measurements,	the	following	samples	from	
the	 ECAT	 surveys	were	 chosen:	 (a)	 a	 severe	 haemophilia	 A	 patient	
sample	 (consensus	 value	 FVIII	 <0.01	IU/mL),	 a	 mild	 haemophilia	 A	
patient	sample	(consensus	value	FVIII	0.16	IU/mL),	a	borderline	hae‐
mophilia	A/low	FVIII	activity	sample	(consensus	value	FVIII	0.42	IU/
mL)	and	a	sample	with	normal	FVIII	activity	 levels	 (consensus	value	
FVIII	1.00	IU/mL).	The	FVIII	activity	levels	were	measured	by	labora‐
tories	participating	 in	the	ECAT	surveys.	Next,	groups	were	created	
of	laboratories	using	calibrator,	activator,	deficient	plasma	and	equip‐
ment	from	one	company	to	investigate	the	impact	of	the	test	system	
on	FVIII	activity	levels.	When	the	reported	FVIII	activity	levels	were	
below	0.01	IU/mL,	they	were	considered	in	the	analysis	as	0.005	IU/
mL.	To	compare	the	FVIII	activity	levels	between	the	three	companies,	
we	used	the	Kruskal‐Wallis	test	as	the	data	were	not	normally	distrib‐
uted.	All	statistics	were	performed	using	SPSS	statistics	for	Windows,	
version	24.0	 (IBM	Corp,	Armonk,	NY,	USA).	A	P‐value	of	<0.05	was	
considered	statistically	significant.
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2.3 | Impact of test system on FVIII activity levels 
in the CSA
The	 impact	 of	 different	 test	 systems	 in	 the	CSA	was	 also	 investi‐
gated.	 FVIII	 activity	 levels	were	 compared	 between	Chromogenix	
Coamatic,	Hyphen	Biomed	and	a	 test	system	from	Siemens	 in	 the	
four	plasma	samples	as	described	under	the	subheading	of	“Impact	
of	test	system	on	FVIII	activity	levels	in	the	OSA.”	The	Kruskal‐Wallis	
test	was	performed	to	analyse	the	data.
2.4 | Contribution of deficient plasma and calibrator
As	not	 all	 laboratories	use	 complete	packages	 from	one	manufac‐
turer,	 deficient	 plasma	or	 a	 calibrator	 from	 another	 company	may	
explain	 the	variation	 in	FVIII	 results.	Unfortunately,	 this	 could	not	
be	 investigated	 in	 the	 ECAT	 surveys,	 as	most	 laboratories	 use	 all	
the	components	in	the	test	system	from	one	company.	For	this	rea‐
son,	we	varied	in	deficient	plasma	on	three	different	machines	and	
its	 reagents	 as	 shown	 in	Table	1.	Calibration	 curves	were	 created	
in	 these	 set‐ups.	Using	 these	calibration	curves,	FVIII	 activity	 lev‐
els	were	measured	 in	duplicate	 in	 three	samples;	one	sample	with	
normal	FVIII	activity	levels	(consensus	value	FVIII	1.00	IU/mL),	mild	
haemophilia	 A	 (consensus	 value	 FVIII	 0.34	IU/mL)	 and	 moderate	
haemophilia	A	(consensus	value	FVIII	0.04	IU/mL).
The	 influence	 of	 the	 calibrator	was	 investigated	 by	measuring	
the	FVIII	activity	levels	in	duplicates	from	the	calibrator	of	Werfen	
(HemosIL	Cal	Plasma)	and	Stago	(STA‐CK	Prest)	in	the	Siemens	set‐
up	as	described	in	Table	1.	As	these	calibrators	have	assigned	values,	
we	 compared	 the	measured	FVIII	 activity	 levels	 of	 the	 calibrators	
with	their	assigned	values.
3  | RESULTS
3.1 | Quantifying variation in FVIII activity 
measurements
In	 the	 different	 surveys,	 on	 average,	 206	 (range	 164‐230)	 lab‐
oratories	 reported	 results	 from	 analyses	 that	 used	 the	OSA	 to	
measure	 FVIII	 activity	 and	 30	 (range	 12‐51)	 laboratories	 used	
the	CSA.	In	surveys	with	lower	FVIII	activity	levels,	the	CV	was	
higher	 (Figure	 1A).	 When	 comparing	 FVIII	 levels	 measured	 by	
OSA	with	 the	 CSA,	 the	 CV	was	 comparable	 between	 the	OSA	
and	the	CSA.	In	addition,	the	median	absolute	FVIII	activity	lev‐
els	 in	 a	 sample	 from	a	 severe	haemophilia	A	patient	were	 simi‐
lar	 in	 the	OSA	 and	CSA,	with	 FVIII	 activity	 levels	 of	 0.005	IU/
mL	 (IQR	 0.005‐0.03	IU/mL)	 for	 the	 CSA	 and	 0.005	IU/mL	 (IQR	
0.005‐0.01	IU/mL)	 for	 the	 OSA.	 When	 comparing	 the	 CV	 be‐
tween	the	laboratories	using	reagents	from	three	companies	for	
the	OSA,	similar	patterns	were	observed.	However,	separation	of	
products	 from	different	 companies	 resulted	 in	higher	CVs	 than	
the	overall	CV	with	a	CV	up	to	158%	maximally	for	the	Werfen	
package	(Figure	1B).
3.2 | Impact of test system on haemophilia severity 
classification
The	impact	of	this	FVIII	variability	on	haemophilia	classification	which	
is	solely	based	on	FVIII	activity	levels	is	significant.	This	is	illustrated	
by	 the	 fact	 that	 the	severe	haemophilia	A	sample	was	classified	as	
moderate	 in	37/139	 (26.6%)	of	 all	OSA	measurements	 (Figure	2D).	
When	classification	is	differentiated	according	to	company	in	samples	
Company
Siemens Stago Werfen
Calibrator Standard	Human	Plasma STA‐Unicalibrator HemosIL	Cal	Plasma
Activator FVIII	Actin	FS STA‐CK	Prest APTT‐SynthASil
Deficient	plasma FVIII	deficient STA	Immunodef	VIII FVIII	Def.	Plasma
Equipment CS	5100	Sysmex STA‐R	Max ACL	TOP500
TA B L E  1  Set‐up	of	the	different	
packages	when	varying	in	deficient	plasma
F I G U R E  1  The	coefficient	of	variation	(CV)	is	higher	when	FVIII	activity	levels	are	lower.	A,	The	CVs	were	calculated	for	both	one‐stage	
assay	(OSA)	and	chromogenic	stage	assay	(CSA).	The	circles	indicate	the	CVs	calculated	from	measurements	with	the	OSA.	The	squares	
reflect	the	CVs	calculated	from	measurements	with	the	chromogenic	substrate	assay	(CSA).	B,	The	CV	of	the	OSA	was	also	calculated	when	
FVIII	activity	levels	were	measured	with	products	from	Siemens	(circles),	Stago	(squares)	and	Werfen	(triangles)
(A) (B)
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tested	 with	 OSA,	 9/45	 (20.0%)	 of	 the	 laboratories	 working	 with	
Siemens	classified	this	sample	as	moderate	or	mild	haemophilia	while	
these	percentages	were	18/38	(47.4%)	for	Stago	and	10/56	(17.9%)	
for	Werfen.	Only	a	small	number	of	laboratories	measured	FVIII	ac‐
tivity	levels	with	CSA.	Overall	with	CSA,	4/30	(13.3%)	classified	the	
severe	haemophilia	A	sample	as	moderate	or	mild.	When	results	are	
differentiated	according	to	company,	misclassification	was	observed	
in	1/8	(12.5%)	for	Chromogenix,	 in	2/14	(14.3%)	for	Hyphen	and	in	
1/8	 (12.5%)	 for	CSA	 testing	with	 Siemens	products.	 In	 conclusion,	
laboratories	using	CSA	misclassified	 severe	haemophilia	A	patients	
less	often.	However,	the	number	of	CSA	measurements	is	small.
3.3 | Impact of test system on FVIII activity levels 
in the OSA
Factor	VIII	 activity	 levels	were	 analysed	 for	 the	 three	major	 com‐
panies	 and	 shown	 in	 Figure	 3.	 In	 a	 sample	 from	 a	 healthy	 person	
(Figure	 3A),	 FVIII	 activity	 levels	 measured	 with	 products	 from	
Werfen	(median	0.93,	IQR	0.88‐0.98	IU/mL)	were	lower	than	FVIII	
activity	 levels	 measured	 by	 products	 from	 Stago	 (median	 1.07,	
IQR	 1.02‐1.14	IU/mL)	 or	 Siemens	 (median	 1.03,	 IQR	 0.97‐1.07	IU/
mL).	We	also	observed	this	trend	in	a	sample	with	0.42	IU/mL	FVIII	
(Figure	3B).	The	differences	between	the	three	manufacturers	in	the	
samples	with	lower	FVIII	activity	levels	were	minimal;	however,	small	
differences	may	have	a	large	clinical	impact.
We	also	investigated	the	influence	of	different	activators	in	the	
set‐up	of	all	products	from	Siemens.	This	company	had	an	activator	
based	on	ellagic	acid	and	one	based	on	silica.	In	addition,	phospho‐
lipid	concentrations	differ	between	these	activators.	We	were	able	
to	compare	these	activators	since	enough	participants	in	the	ECAT	
survey	used	these	activators.	We	observed	equal	FVIII	activity	val‐
ues	between	the	activators	in	all	four	plasma	samples	(Figure	S1).
3.4 | Impact of test system on FVIII activity levels 
in the CSA
For	 the	CSA,	 three	 kits	were	most	 oftenly	 used:	 (a)	 Chromogenix	
Coamatic	 (n	=	8‐13),	 (b)	 Hyphen	 Biomed	 (n	=	14‐23)	 and	 (c)	 FVIII	
Chromogenic	assay	from	Siemens	(n	=	7‐10).	We	compared	the	FVIII	
activity	levels	obtained	by	the	three	most	commonly	used	kits	and	
observed	no	consistent	differences	in	FVIII	activity	levels	between	
the	kits	(Figure	4).	Some	small	differences	were	found	as	the	kit	from	
Siemens	had	higher	FVIII	activity	 levels	 in	the	normal	sample	 (me‐
dian	1.02,	 IQR	0.98‐1.09	IU/mL)	compared	to	the	kit	from	Hyphen	
Biomed	(median	0.94,	IQR	0.88‐0.98	IU/mL).
3.5 | Effect of deficient plasma on FVIII activity
A	possible	explanation	 for	 the	variation	 in	 the	OSA	may	be	varia‐
tion	in	the	behaviour	of	the	deficient	plasma.	Deficient	plasma	was	
therefore	also	exchanged	between	company	set‐ups.	We	observed	
that	using	deficient	plasma	from	another	company	did	not	influence	
FVIII	activity	levels	in	samples	of	a	moderate	haemophilia	A	patient	
or	in	samples	containing	FVIII	activity	levels	around	0.40	IU/mL	FVIII	
(Figure	5).	However,	 in	a	sample	 from	a	healthy	person,	Stago	de‐
ficient	plasma	causes	slightly	 lower	FVIII	 results.	For	example,	 the	
FVIII	activity	level	in	a	Siemens	set‐up	using	Stago	deficient	plasma	
results	in	a	FVIII	level	of	1.00	IU/mL,	while	Siemens	deficient	plasma	
F I G U R E  2  The	distribution	of	the	FVIII	
activity	levels	measured	by	one‐stage	
assay	(OSA).	FVIII	levels	are	shown	when	
measured	with	company	set‐ups	from	
Siemens,	Stago	or	Werfen
(A) (B)
(C) (D)
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resulted	 in	 1.11	IU/mL	 and	Werfen	 in	 1.09	IU/mL	 FVIII.	More	 im‐
portantly,	results	obtained	with	Werfen	equipment,	were	in	general	
lower	compared	 to	FVIII	 results	acquired	 from	Stago	and	Siemens	
equipment.	The	average	FVIII	activity	of	the	normal	sample	meas‐
ured	with	Werfen	equipment	was	0.86	IU/mL	while	this	was	1.08	IU/
mL	 for	Stago	and	1.07	IU/mL	 for	Siemens.	This	experiment	 shows	
that	not	only	FVIII	deficient	plasma	but	other	causes	may	have	an	
effect	on	the	variation	in	FVIII	measurement.
3.6 | Differences in calibrator
The	 influence	 of	 the	 calibrator	was	 determined	 by	measuring	 the	
FVIII	activity	 in	each	calibrator	and	comparing	the	measured	FVIII	
activity	value	 to	 the	assigned	value	 from	 the	manufacturer,	based	
on	 the	WHO	 international	 standard.	 The	 FVIII	 levels	 in	 both	 the	
STA‐Unicalibrator	and	the	HemosIL	calibrator	plasmas	were	meas‐
ured	 in	 duplicates	 on	 the	 Siemens	 set‐up	 as	 described	 in	 Table	 1.	
The	assigned	calibration	value	was	1.10	and	0.98	IU/mL	for	the	STA‐
Unicalibrator	 and	 the	 HemosIL,	 respectively,	 while	 the	 measured	
FVIII	activity	levels	of	these	calibrators	were	1.21	and	1.12	IU/mL.	
As	these	values	differed	from	the	assigned	value,	it	may	be	that	the	
calibrator	 is	one	of	the	causes	that	results	 in	the	variation	 in	FVIII	
activity	measurements.
4  | DISCUSSION
The	aim	of	this	study	was	to	quantify	and	understand	in	more	de‐
tail	 the	 variation	 in	 FVIII	 activity	 measurements	 when	 testing	 by	
OSA	and	CSA	 in	 surveys	 conducted	by	 the	ECAT	external	 quality	
control.	We	showed	that	the	CV	in	FVIII	measurements	has	an	 in‐
verse	 relationship	with	 FVIII	 activity	 levels.	 In	 addition,	 measure‐
ments	performed	with	OSA	from	the	Werfen	package	showed	lower	
FVIII	activity	levels	compared	to	measurements	with	the	Stago	and	
Siemens	package.	The	explanation	may	be	due	to	differences	in	as‐
signed	values	to	the	calibrator.
The	 results	 of	 this	 study	 showed	 that	 the	 variation	 between	
laboratories	 is	higher	when	FVIII	activity	 levels	are	 lower,	both	 in	
the	 OSA	 and	 CSA.	 These	 results	 are	 consistent	 with	 the	 results	
by	Verbruggen	et	al12	 in	2008,	who	also	showed	a	J‐shaped	rela‐
tionship	between	FVIII	activity	levels	and	CV,	for	FVIII	results	pre‐
dominantly	from	the	OSA.	In	their	study,	the	CV	increased	strongly	
below	0.20	IU/mL	with	a	maximal	CV	between	30%	and	40%.	Our	
study	 demonstrated	much	 higher	CVs	with	 a	maximum	of	 121%.	
This	may	be	due	to	the	fact	that	Verbruggen	et	al	showed	the	CVs	
for	samples	with	FVIII	activity	levels	between	0.10‐0.20	IU/mL	and	
not	lower.	Furthermore,	it	may	be	that	that	haemophilia	treatment	
centres	may	be	more	accurate	in	general	and	may	more	often	per‐
form	both	OSA	and	CSA.	A	subanalysis	was	performed	comparing	
the	variability	of	the	two	assays	with	the	data	from	centres	carry‐
ing	out	both	assays,	and	no	difference	in	CV	was	observed	(Figure	
S2).	 The	CV	 increases	 substantially	 in	 samples	with	 low	FVIII	 ac‐
tivity	 levels	 (Figure	 1),	 although	 absolute	 differences	 in	 FVIII	 ac‐
tivity	levels	remain	small.	Therefore,	it	is	important	to	realise,	that	
although	these	differences	are	small,	 they	have	significant	clinical	
consequences	as	early	initiation	of	prophylactic	treatment	is	largely	
dependent	on	test	results	and	subsequent	classification	of	haemo‐
philia	severity.
F I G U R E  3  Combination	of	deficient	
plasma,	equipment,	calibrator	and	
activator	from	Werfen	causes	lower	
factor	VIII	(FVIII)	activity	levels	when	
FVIII	>0.40	IU/mL	compared	to	Stago	and	
Siemens.	The	red	dots	are	the	results	from	
each	laboratory.	The	black	line	represents	
the	median.	The	error	bars	represent	the	
interquartile	range.	Statistical	significance	
is	indicated	as	*P	<	0.05,	**P	<	0.01,	***	
P	<	0.001
(A) (B)
(C) (D)
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Factor	 VIII	 activity	 measurements	 were	 slightly	 lower	 when	
measured	with	products	 from	Werfen,	but	 statistically	 significant.	
It	was	impossible	in	the	ECAT	surveys	to	evaluate	the	cause	of	this	
lower	FVIII	activity	by	evaluating	each	component	of	the	OSA	sep‐
arately,	 as	 laboratories	 often	 utilise	 calibrator,	 activator,	 deficient	
plasma	 and	 equipment	 from	 one	manufacturer.	We	 attempted	 to	
specify	the	cause	of	this	variation	in	FVIII	measurements	by	evalu‐
ating	deficient	plasmas	from	different	companies	(Figure	5)	in	sep‐
arate	experiments.	No	consistent	differences	were	observed	when	
exchanging	 deficient	 plasma,	 for	 example,	 deficient	 plasma	 from	
Stago	 in	 a	Siemens	 set‐up.	Despite	 the	 fact	 that	 small	 differences	
were	found,	results	should	be	interpreted	with	caution.	In	general,	
a	small	amount	of	factor	concentrate	may	still	be	present	in	plasma	
samples	 derived	 from	 severe	 haemophilia	 A	 patients	 due	 to	 prior	
treatment	and	an	insufficient	wash	out	period,	thus	influencing	FVIII	
activity	levels.	In	addition,	the	metrological	traceability	is	only	based	
on	a	consensus	model	and	no	golden	standard	is	available	for	FVIII	
measurements.	This	again	raises	the	question	how	to	perform	hae‐
mophilia	classification	based	on	the	measured	FVIII	levels	as	it	is	still	
unclear	which	FVIII	activity	assay	is	most	optimal.
Another	cause	for	the	variation	in	OSA	FVIII	measurements	may	
be	 the	calibrator.	As	we	 found	a	higher	FVIII	 activity	value	of	 the	
Werfen	calibrator	in	the	Siemens	set‐up,	1.12	IU/mL	instead	of	the	
assigned	0.98	IU/mL,	 this	may	 lead	 to	an	underestimation	of	FVIII	
levels	in	the	Werfen	package,	explaining	the	lower	FVIII	activity	re‐
sults	that	we	have	observed.	However,	as	previously	mentioned,	we	
do	not	know	the	true	values.	It	 is	 important	to	realise	that	despite	
the	 fact	 that	 companies	 calibrate	 their	 reference	material	 against	
plasma	FVIII	international	standards,	differences	may	still	be	present	
in	FVIII	values	between	the	various	test	systems.
Several	other	hypothetical	explanations	exist	which	may	explain	
variation	 in	 both	 assays.	 Firstly,	 of	 course,	 preanalytical	 variables	
may	 influence	 the	 measurements.18,19	 However,	 in	 the	 ECAT	 sur‐
veys,	 these	preanalytical	variables	are	not	applicable	as	all	 labora‐
tories	 receive	 the	 same	 lyophilized	 plasma	 sample.	 Nevertheless,	
differences	in	dissolving	lyophilized	plasma	may	also	be	considered	a	
preanalytical	variable.	Secondly,	variation	in	characteristics	of	differ‐
ent	batches	of	reagents,	deficient	plasmas	and	calibrators	may	also	
cause	differences	in	FVIII	activity	levels.	In	the	ECAT	surveys,	many	
different	 lot	numbers	were	used	by	the	different	 laboratories,	and	
therefore,	we	do	not	expect	 that	 typical	properties	of	 a	 single	 lot	
will	be	able	to	influence	the	results	from	the	ECAT	surveys.	Finally,	
previous	studies	have	shown	that	some	activators	(STA	Cephascreen	
[Stago]	and	Actin	FS	[Siemens])	are	not	optimal	in	diagnosing	severe	
F I G U R E  4  No	consistent	differences	in	factor	VIII	(FVIII)	activity	levels	between	mostly	wide	used	chromogenic	assays.	The	red	dots	
are	the	results	from	each	laboratory.	The	black	line	represents	the	median.	The	error	bars	represent	the	interquartile	range.	Statistical	
significance	is	indicated	as	*P	<	0.05,	**P	<	0.01,	***	P	<	0.001
(A) (B)
(C) (D)
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haemophilia	A	patients	which	may	also	have	influenced	the	FVIII	ac‐
tivity	levels	found	in	this	study.12
High	between‐laboratory	CVs	may	 influence	diagnoses	of	hae‐
mophilia	 A	 patients	 between	 hospitals	 as	 reported	 previously.4 
Already,	small	absolute	differences	in	FVIII	activity	may	result	in	mis‐
classification	and	suboptimal	treatment.	This	emphasizes	the	impor‐
tance	of	the	following	three	aspects	in	haemophilia	management	(a)	
performance	of	other	relevant	tests	such	as	DNA	mutation	analysis	
aid	 in	 classification	 as	well	 as	 repeated	 testing,	 taking	 lowest	 lev‐
els	as	basis	for	treatment;	(b)	adjustment	of	treatment	is	obligatory	
when	test	results	do	not	correspond	with	clinical	symptoms;	and	(c)	
treatment	of	haemophilia	patients	 in	certified	and	specialized	cen‐
tres	 in	which	 (paediatric)	haematologists	 specialized	 in	 rare	bleed‐
ing	disorders	and	the	diagnostic	criteria	and	clinical	presentation	of	
these	disorders	is	of	utmost	importance.	Laboratories	should	also	be	
aware	that	incorrect	patient	diagnosis	is	still	possible	despite	excel‐
lent	analytical	performance	in	quality	control	surveys.	In	addition,	to	
reduce	the	large	between‐laboratory	CV	both	in	the	OSA	and	CSA,	
standardization	is	required	for	example	by	an	external	quality	control	
as	the	ECAT	foundation.	Current	developments	in	method	harmoni‐
zation	may	also	reduce	the	large	between‐laboratory	variability.
In	conclusion,	FVIII	activity	levels	are	negatively	associated	with	
CV	 for	 both	 the	OSA	 and	CSA.	 The	 variation	 in	 the	OSA	may	 be	
attributed	to	the	different	components	used	in	current	FVIII	assays.	
As	no	golden	standard	is	available	for	FVIII	measurements,	it	is	not	
possible	to	judge	which	result	is	superior.	Future	studies	focusing	on	
standardization	of	FVIII	measurements	and	 in‐depth	education	on	
available	tests	are	required	to	further	improve	haemophilia	diagnosis	
and	patient	management.
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